Key Highlights

  • ARS Pharmaceuticals (NASDAQ:SPRY) changed hands at USD 3.41 on Thursday, November 19, 2026, a decline of 7.62% in intraday market data that implies a prior close near USD 3.69 (calculated).
  • Third-quarter Revenue reached USD 37.7 million, up from USD 32.5 million a year earlier, and U.S. net product revenue from neffy rose to USD 33.4 million from USD 31.3 million.
  • Losses contracted to a USD 35.6 million net loss, USD 0.36 a share, from a USD 51.2 million loss, USD 0.52 a share, once selling expenses fell from USD 74.8 million to USD 43.5 million.
  • At September 30, 2026 the company held USD 138.4 million across cash and short-term holdings, down from roughly USD 245.0 million at the close of 2025, while Leadership targets breakeven Cash Flow by late 2027.

No Company Announcement Accompanies the Share Decline

Shares changed hands at USD 3.41 on November 19, 2026, following a 7.62% retreat, but nothing in the way of a company statement, regulatory filing or analyst note dated November 17 through 19 could be linked to that decline. The most recent hard news is the third-quarter report released November 5, 2026. The product, neffy, is a needle-free epinephrine spray aimed at serious allergic episodes such as anaphylaxis, and its commercial rollout remains at an early stage. Low-priced healthcare shares can drift lower on thin trading or profit-taking without any fresh disclosure, so the move alone reveals little about the underlying Business or its sales trajectory.

Neffy Revenue Growth Lags Rising Prescriber Demand

U.S. net product revenue from neffy climbed from USD 31.3 million to USD 33.4 million, roughly 6.7% (calculated). Management attributed the gap between that figure and faster end-user Demand to swings in channel inventory. Supply revenue of USD 2.6 million and collaboration revenue of USD 1.7 million made up the rest of the top line. Published coverage, a single report, said commercial coverage slipped to above 80% of lives and that revenue came in below what the market had anticipated. SG&A outlays shrank once the company halted linear TV and broad consumer ads, while R&D rose to USD 18.3 million, inflated by a one-time USD 12.5 million license fee.

Cash Runway, Term Debt and the ARS-2 Readout Ahead

Cash and short-term investments totalled USD 138.4 million, consisting of USD 25.6 million in cash and USD 112.7 million in short-term holdings. Management guides combined selling, administrative and research outlays of USD 114 million to USD 126 million for the second half of 2026, stock-based compensation included. Published coverage placed term-loan debt around USD 121.8 million, though that figure is not confirmed here. The company reported 100,248,400 shares outstanding on September 30, 2026. Interim Phase 2b findings for ARS-2 in chronic spontaneous urticaria are the next milestone, slated for the first quarter of 2027, and a miss against the breakeven aim would raise the likelihood of new financing.

Where Things Stand

No announced company event explains the 7.62% slide. ARS Pharmaceuticals (NASDAQ:SPRY) last reported on November 5, 2026, with revenue growth and a narrower loss, but neffy sales trailed demand and cash dropped roughly USD 107 million from December 31, 2025, a calculated figure. A share priced below USD 5 can swing on a handful of trades, and quoted moves may reverse. Investors will watch fourth-quarter neffy revenue, insurance coverage progress, the spending range and the ARS-2 readout in early 2027.